DepoMed (NASDAQ: DEPO) reported Q1 EPS of ($0.13), $0.14 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $31.7 million versus the consensus estimate of $33.8 million.

DepoMed sees FY2015 revenue of $310-335 million, versus the consensus of $305.02 million.

For earnings history and earnings-related data on DepoMed (DEPO) click here.